ENVB

Enveric Biosciences Inc

1.52

Nov 12 • 3:59 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Peers: CMND PBM DRUG GHRS SILO VTGN KTTA JUNS RLMD ANVS

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	6.80M
Enterprise Value	-1.50M
Income	-12.09M
Sales	0.00M
Book/sh	2.05
Cash/sh	1.86
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	6
IPO	Aug 22, 1995

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.74
P/C	0.82
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	10.21
Current Ratio	10.21
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-16.46
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	75.07% 67.96%
Sales past 3/5Y	- -
EPS Y/Y TTM	87.05%
Sales Y/Y TTM	-
EPS Q/Q	93.48%
Sales Q/Q	-
Earnings	Aug 14 AMC
EPS/Sales Surpr.	- -

Insider Own	1.64%
Insider Trans	0.00%
Inst Own	15.89%
Inst Trans	8.92%
ROA	-139.75%
ROE	-170.04%
ROIC	-108.00%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	5.07%
SMA50	3.70%
SMA200	-20.07%
Trades

Shs Outstand	4.48M
Shs Float	4.40M
Short Float	0.45%
Short Ratio	0.27
Short Interest	0.02M
52W High	13.25 -88.53%
52W Low	1.17 29.90%
Volatility	6.86% 7.34%
ATR (14)	0.10
RSI (14)	56.62
Beta	1.20
Rel Volume	0.00
Avg Volume	71.87K
Volume	0

Perf Week	8.57%
Perf Month	10.95%
Perf Quarter	-0.98%
Perf Half Y	-33.62%
Perf YTD	-58.13%
Perf Year	-74.58%
Perf 3Y	-99.47%
Perf 5Y	-99.99%
Perf 10Y	-100.00%
Recom	1.00
Target Price	1800.00
Prev Close	1.52
Price	1.52
Change %	0.00%

Nov-04-26 07:00AM	Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study (Business Wire)
Oct-21-26 08:00AM	Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies (Business Wire)
Sep-15-26 08:00AM	Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series (Business Wire)
Sep-01-26 08:30AM	Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference (Business Wire)
Aug-14-26 04:05PM	Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026 (Business Wire)
08:00AM	Loading…
Aug-05-26 08:00AM	Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003 (Business Wire)
Jul-28-26 08:00AM	Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development (Business Wire)
Jun-29-26 08:00AM	Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit (Business Wire)
Jun-16-26 09:28AM	Enveric Biosciences Announces Participation in 2026 BIO International Convention (Business Wire) -7.43%
Jun-09-26 08:00AM	Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day (Business Wire) -8.57%
May-19-26 08:00AM	Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003 (Business Wire)
May-15-26 08:00AM	Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026 (Business Wire)
May-13-26 08:00AM	Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders (Business Wire)
May-05-26 08:00AM	Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model (Business Wire)
Apr-28-26 07:33AM	Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors (PR Newswire)
10:30AM	Loading…
Apr-24-26 10:30AM	BC-Most Active Stocks (Associated Press) +25.37%
Apr-21-26 08:00AM	Enveric Biosciences to Participate in a Panel Discussion at Needhams Virtual Psychedelics Forum (Business Wire) -7.67%
Apr-20-26 10:30AM	BC-Most Active Stocks (Associated Press) +100.55%
Apr-17-26 06:28PM	Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules (Business Wire) -22.55%
Apr-16-26 08:00PM	Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules (Business Wire) +15.76%
Mar-31-26 08:00AM	Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates (Business Wire) +8.38%
Mar-27-26 05:40PM	Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025 (Business Wire)
Mar-18-26 08:00AM	Enveric Biosciences Announces Registration of Five Trademarks (Business Wire)
Feb-25-26 08:01AM	Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested (Benzinga) +9.09%
08:00AM	Enveric Biosciences Announces Withdrawal of Petition Against Its Patent (Business Wire)
Feb-22-26 07:43PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Feb-20-26 08:09AM	Enveric Biosciences reports EB-003 receptor engagement assay data (TipRanks) -8.26%
Feb-19-26 08:00AM	Enveric Advances Lead Drug With New Findings On Key Brain Receptor Signals (Benzinga) +8.04%
08:00AM	Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data (Business Wire)
Jan-29-26 08:00AM	Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option (Business Wire) -12.03%
05:00PM	Loading…
Jan-28-26 05:00PM	Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (Business Wire) -21.31%
08:00AM	Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (Business Wire)
Dec-30-25 08:10AM	Enveric Biosciences announces issuance of U.S. patent (TipRanks) +5.11%
Dec-29-25 08:00AM	Enveric Biosciences Announces Patent Issuance (Business Wire) -9.49%
Dec-15-25 09:00AM	ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman (Business Wire)
08:03AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Dec-12-25 04:46PM	Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds (Business Wire)
Dec-11-25 01:43PM	Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds (Business Wire) -47.34%
Dec-09-25 08:00AM	Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates (Business Wire)
Dec-04-25 08:00AM	Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During J.P. Morgan Week 2026 (Business Wire)
Dec-01-25 08:38AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Nov-26-25 08:00AM	Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates (Business Wire)
Nov-14-25 04:05PM	Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results (Business Wire) -5.87%
Oct-23-25 08:00AM	Enveric Biosciences Announces Reverse Stock Split (Business Wire) -8.26%
Oct-19-25 06:06PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Oct-16-25 08:30AM	Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance (Business Wire) -12.44%
Oct-15-25 02:48PM	AbbVie's Bretisilocin Hit With Enveric IP Claim (GuruFocus.com) +24.36%
08:30AM	Enveric Biosciences hires Fish & Richardson to defend patent tied to AbbVie deal (Investing.com)
08:00AM	Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal (Business Wire)
Oct-14-25 09:00AM	Enveric Biosciences to Explore Digital Asset Treasury Opportunities (Business Wire) +12.08%
Oct-02-25 08:45AM	Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials (Business Wire) +17.37%
Sep-18-25 04:30PM	Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds (Business Wire)
Sep-17-25 09:24AM	Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds (Business Wire) -29.30%
08:00AM	Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery (Business Wire)
Sep-16-25 08:45AM	Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission (Business Wire)
Sep-03-25 08:30AM	Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Sep-02-25 08:30AM	Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA (Business Wire)
Aug-28-25 08:30AM	Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications (Business Wire) -13.10%
Aug-14-25 08:00AM	Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results (Business Wire)
Jul-23-25 08:03AM	Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series (Business Wire)
Jul-20-25 07:00PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jul-15-25 09:03AM	Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD) (Business Wire) -8.21%
Jun-27-25 11:50AM	Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial (TipRanks)
Jun-24-25 09:03AM	Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003 (Business Wire)
Jun-16-25 10:46AM	Enveric Biosciences Announces Participation in 2025 BIO International Convention (Business Wire)
Jun-10-25 09:03AM	Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders (Business Wire)
Jun-03-25 09:00AM	Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds (Business Wire)
May-29-25 09:10AM	Enveric Biosciences announces results from EB-003 trial (TipRanks)
May-28-25 09:03AM	Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003 (Business Wire) -5.51%
May-20-25 08:00AM	Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease (Business Wire)
May-14-25 04:15PM	Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results (Business Wire) -8.13%
Mar-31-25 08:00AM	Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024 (Business Wire) -5.44%
Mar-17-25 01:40PM	Enveric Biosciences Participating in BIO-Europe Spring (Business Wire)
Mar-07-25 10:05AM	Enveric Biosciences launches RFP solicitation process for PsyAI trademark (TipRanks) -5.21%
Mar-06-25 10:00AM	Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark (Business Wire) -8.57%
Feb-28-25 11:30AM	Psychedelic: GH Research, Compass Pathways report earnings results (TipRanks) +32.08%
Feb-27-25 09:30AM	Enveric Biosciences CEO Issues Letter to Shareholders (Business Wire) -7.83%
Feb-25-25 01:30PM	Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent (Business Wire) -13.87%
Feb-04-25 08:00AM	Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease (Business Wire)
Feb-03-25 05:00PM	Enveric Biosciences Announces Closing of $5 Million Public Offering (Business Wire) -13.40%
Jan-31-25 09:17AM	Enveric Biosciences Prices $5 Million Public Offering; Shares Drop 40% in Premarket Trading (GuruFocus.com) -46.41%
Jan-30-25 08:14PM	Enveric Biosciences Announces Pricing of $5 Million Public Offering (Business Wire) -9.30%
04:01PM	Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office (Business Wire)
Jan-06-25 09:10AM	Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During "J.P. Morgan Week 2025" (Business Wire)
Dec-02-24 08:00AM	Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds (Business Wire)
Nov-25-24 09:00AM	Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior (Business Wire)
Nov-18-24 07:19AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Nov-14-24 04:05PM	Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results (Business Wire) -8.06%
Nov-12-24 09:00AM	Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002 (Business Wire) -7.39%
Nov-04-24 10:36AM	Enveric Biosciences Announces Broad Range of Patent Issuances (Business Wire) -5.63%
Oct-15-24 08:00AM	Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003 (Business Wire)
Sep-26-24 08:30AM	Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop (Business Wire) -5.78%
Sep-25-24 08:30AM	Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit (Business Wire) +7.14%
Sep-04-24 08:00AM	Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-13-24 08:00AM	Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries License for Treatment of Radiation Dermatitis and Other Conditions (Business Wire)
Aug-12-24 05:30PM	Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results (Business Wire)
Jul-25-24 08:00AM	Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally (Business Wire)
Jul-15-24 09:02AM	Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement (Business Wire)
Jul-10-24 08:00AM	Enveric Biosciences Announces Patent Granted for Drug Candidate (Business Wire) +5.82%
Jun-28-24 08:00AM	Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB) (GlobeNewswire)

Show Previous News

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

CEO & DirectorDr. Joseph Edward Tucker Ph.D.

Chief Financial OfficerMr. Kevin M. Coveney CPA

Chief Innovation OfficerDr. Peter J. Facchini Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

ENVB

Enveric Biosciences Inc

Upgrade your Finviz experience

All the Features.
Half the Price.